Balyasny Asset Management L.P. purchased a new stake in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 38,021 shares of the biotechnology company's stock, valued at approximately $527,000. Balyasny Asset Management L.P. owned 0.07% of Prothena at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Bank of America Corp DE lifted its holdings in shares of Prothena by 45.0% during the 4th quarter. Bank of America Corp DE now owns 119,007 shares of the biotechnology company's stock valued at $1,648,000 after buying an additional 36,944 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Prothena by 74.4% during the 4th quarter. BNP Paribas Financial Markets now owns 97,383 shares of the biotechnology company's stock valued at $1,349,000 after buying an additional 41,541 shares during the period. Boxer Capital Management LLC bought a new position in shares of Prothena during the 4th quarter valued at $9,556,000. PDT Partners LLC lifted its holdings in shares of Prothena by 15.0% during the 4th quarter. PDT Partners LLC now owns 127,203 shares of the biotechnology company's stock valued at $1,762,000 after buying an additional 16,549 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of Prothena by 8.5% during the 4th quarter. Northern Trust Corp now owns 404,496 shares of the biotechnology company's stock valued at $5,602,000 after buying an additional 31,841 shares during the period. 97.08% of the stock is owned by institutional investors.
Prothena Stock Down 4.5%
PRTA stock traded down $0.33 during trading on Wednesday, hitting $6.96. 218,852 shares of the company's stock traded hands, compared to its average volume of 589,980. The firm has a market capitalization of $374.58 million, a P/E ratio of -3.04 and a beta of 0.11. The business has a fifty day simple moving average of $10.08 and a two-hundred day simple moving average of $13.10. Prothena Co. plc has a 1 year low of $6.47 and a 1 year high of $25.42.
Prothena (NASDAQ:PRTA - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.92) by ($0.20). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The firm had revenue of $2.83 million during the quarter, compared to analysts' expectations of $8.18 million. During the same period in the prior year, the firm posted ($1.34) earnings per share. Prothena's revenue for the quarter was up 5500.0% compared to the same quarter last year. On average, equities research analysts predict that Prothena Co. plc will post -4.04 EPS for the current fiscal year.
Analysts Set New Price Targets
PRTA has been the subject of several analyst reports. Oppenheimer upped their price objective on Prothena from $58.00 to $62.00 and gave the stock an "outperform" rating in a research note on Friday, February 7th. StockNews.com upgraded Prothena from a "sell" rating to a "hold" rating in a research note on Monday, February 24th. JMP Securities reduced their price objective on Prothena from $80.00 to $78.00 and set a "market outperform" rating for the company in a research note on Friday, May 9th. Royal Bank of Canada cut their price target on Prothena from $24.00 to $20.00 and set a "sector perform" rating for the company in a research note on Friday, February 21st. Finally, Cantor Fitzgerald upgraded Prothena to a "strong-buy" rating in a research report on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $51.71.
Check Out Our Latest Stock Report on Prothena
Prothena Profile
(
Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Recommended Stories
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
